Acute Respiratory Infection Clinical Trial
Official title:
Meditation and Exercise for Prevention of Acute Respiratory Infection
The overarching goal of this project is to determine whether mind-body practices such as meditation or exercise can reduce the public health burden of acute respiratory infection. A major secondary goal is to determine whether mindfulness meditation or moderately strenuous exercise can enhance immune processes such as antibody response to influenza vaccination (flu shots). Finally, we want to investigate the influence of stress, optimism, anxiety and positive and negative emotion on immunity and resistance to respiratory infection.
ABSTRACT
Background Preliminary evidence suggests that meditation and exercise may work through
interacting psychological and physiological pathways to influence the immune system and
reduce infectious respiratory disease.
Methods In this study, women and men aged 50 and older will be randomized to: 1) an 8-week
behavioral training program in mindfulness meditation, 2) an intensity, duration and
location-matched 8-week exercise training program, or 3) a waiting list control group.
Sample size will be N=150 enrolled, with N=50 in each group. The main patient-oriented
outcome will be severity-adjusted total days of acute respiratory infection (ARI) illness,
as self-reported on the Wisconsin Upper Respiratory Symptom Survey (WURSS-24), a validated
questionnaire outcome measure. Nucleic acid based viral identification will verify all
symptomatic infections, and the cytokine IL-8 and nasal neutrophil from nasal wash will
serve as biomarkers of illness severity. Biomarkers of immune function will include antibody
response to influenza immunization (serum IgG, mucosal IgA) and cytokines IFN-γ and IL-10
from cultured ex vivo lymphocytes. Questionnaire measures assessing perceived stress,
positive and negative emotion, optimism, and anxiety will be analyzed as potential mediators
of immunomodulation and illness prevention.
Timeframe / logistics This will be a 2-year project, with 2 cohorts conducted during a
single cold season. The first cohort of N=60 will be randomized and begin interventions in
September 2009. The second cohort of N=90 will be randomized and begin interventions in
January 2010. Tri-valent influenza vaccination will occur on week 6 of behavioral
interventions in both cohorts. Blood for antibody titer and ex vivo cytokine assay will be
drawn at baseline, at the end of the 8-week session, and once again 3 months later. Nasal
swab for IgA will be done at the same times. Participants will be followed with telephone
contact every 2 weeks, with monthly questionnaire instruments, and with daily
self-assessments during ARI illness episodes.
Analysis ANOVA-based models will assess effects of meditation and exercise on immune markers
and ARI illness. Psychological measures will be assessed as potential mediators of effects
of meditation and exercise on ARI illness. Generalized estimating equations, random-effects
pattern-mixture models, and hierarchical linear models will be used to assess longitudinal
effects, interactions, and covariate mediation.
Section 2. Specific Aims
2.1. Background Acute respiratory infection (ARI) is a leading cause of morbidity and
mortality. Influenza is the most pathogenic of the many viruses involved, and hence merits
special attention. Protective and ameliorative immune mechanisms are poorly understood, but
are associated with various indicators of mental as well as physical health.
A broad literature suggests that regular exercise affects the immune system, positively
influences mental health, and protects against ARI illness. A separate and smaller body of
evidence suggests that mindfulness meditation may lead to lower stress levels and better
mental and physical health. Published evidence from our own study suggests that meditation
may enhance antibody (serum IgG) response to influenza vaccination (flu shot) [1].
2.2. Methods & Aims The proposed randomized controlled trial (RCT) will test for effects of
meditation and exercise on incidence and severity of ARI illness during an 8-month
observation period. Participants (N=150) will be randomized to 1) an 8-week training program
in mindfulness meditation, 2)an attention, duration and location-matched program in moderate
intensity exercise, or 3) a waiting list control group. Each ARI illness episode will be
assessed by a validated questionnaire outcomes instrument, verified with nucleic acid based
multiplex viral identification system, and assessed for inflammation with IL-8 assay and
neutrophil count from nasal wash. Immunological measures will include antibody response to
flu shot (both serum IgG and mucosal IgA) and cytokine indicators of TH1 (IFN-γ) and TH2
(IL-10) immune response, as measured in stimulated ex vivo lymphocyte cell culture.
Psychological domains to be assessed include perceived stress, positive and negative
emotion, anxiety, and optimism. Immune biomarkers and psychological domains will be assessed
as consequences of behavioral interventions, and as predictors of ARI illness. Finally, we
will attempt to disentangle the mediating effects of psychological health on immune
mechanisms and ARI illness. For example, one hypothesis is that meditation influences the
immune system through reduction of stress-related immune dampening mechanisms. That
hypothesis would receive support if perceived stress and ARI illness were lowest in the
meditation group, and if perceived stress associated more strongly with immune biomarkers
and ARI measures than did measures of other psychological domains. We expect that both
exercise and meditation will improve psychological health, influence immune biomarkers, and
reduce ARI illness burden. However, current evidence is not sufficient to estimate the
relative magnitude of these effects, nor to confidently predict whether cellular and/or
antibody-mediated immune mechanisms will be implicated.
2.3 Null hypotheses - 2.3.1 Compared to control, an 8-week training program in mindfulness
meditation will not lead to statistically significant reductions in number of
severity-weighted days of ARI illness. 2.3.2 Compared to control, a matched 8-week exercise
training program will not lead to significant reductions in ARI illness. 2.3.3 Meditation
training will not enhance either antibody response to flu shot (serum IgG, mucosal IgA), or
cytokine expression linked to TH1 and TH2 cell-mediated immune pathways (IFN-γ, IL-10).
2.3.4 Exercise training will not enhance either antibody response to flu shot or cytokine
expression from cultured lymphocytes. 2.3.5 Mindfulness meditation training will not lead to
improvements in measures of psychological health (perceived stress, positive and negative
emotion/affectivity, anxiety, optimism). 2.3.6 Exercise training will not improve these
psychological measures. 2.3.7 Immune biomarkers will not predict ARI outcomes. 2.3.8
Psychological measures will not predict ARI outcomes. 2.3.9 The effects of meditation and
exercise on psychological measures, immune biomarkers, and ARI illness will not be
distinguishable from each other. 2.3.10 Observed effects of meditation and exercise on ARI
outcomes will not be explained by either psychological measures or biomarkers of immune
mechanisms.
2.4 Justification Influenza and other acute viral infections are responsible for tremendous
health burden. Antibody-mediated immunity, responding to vaccination or natural exposure, is
only partially effective in conferring protection. Current evidence suggests that
cell-mediated immune mechanisms are important in this process. Both antibody-mediated and
cell-mediated immune mechanisms have been linked to psychological domains, and appear to
decline with aging. Preliminary evidence suggests that both mindfulness meditation and
moderate intensity exercise may be at least partially effective in modifying immune response
and reducing infectious illness burden. No studies have compared these 2 quite different
behavioral intervention techniques. This proposed research would provide new knowledge
regarding effects of meditation and exercise training on ARI illness, and immunological and
psychological pathways involved.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03943654 -
Improving Nighttime Access to Care and Treatment (Part 2)
|
||
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Not yet recruiting |
NCT05902702 -
Isotonic Saline for Children With Bronchiolitis
|
N/A | |
Not yet recruiting |
NCT04525118 -
Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
|
||
Completed |
NCT01431469 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil
|
N/A | |
Completed |
NCT00981513 -
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
|
Phase 4 | |
Recruiting |
NCT06183229 -
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
|
Phase 3 | |
Completed |
NCT03274310 -
FluSAFE: Flu SMS Alerts to Freeze Exposure
|
N/A | |
Completed |
NCT03736096 -
Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
|
||
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT03028077 -
Effects of GS-3K8 and GINst15 on Acute Respiratory Illness
|
N/A | |
Enrolling by invitation |
NCT01286285 -
Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria
|
N/A | |
Completed |
NCT03840135 -
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
|
Phase 3 | |
Completed |
NCT01488435 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age
|
N/A | |
Not yet recruiting |
NCT00545961 -
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
|
Phase 4 | |
Completed |
NCT05273619 -
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
|
Phase 3 | |
Recruiting |
NCT04415827 -
Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases
|
N/A | |
Completed |
NCT03459391 -
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT04938323 -
Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly
|
Phase 2/Phase 3 |